| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | GNF-2 | GDSC1000 | pan-cancer | AAC | -0.069 | 0.3 |
| mRNA | tivozanib | CTRPv2 | pan-cancer | AAC | 0.052 | 0.3 |
| mRNA | cabozantinib | CTRPv2 | pan-cancer | AAC | 0.048 | 0.3 |
| mRNA | tandutinib | CTRPv2 | pan-cancer | AAC | 0.049 | 0.3 |
| mRNA | IPA-3 | GDSC1000 | pan-cancer | AAC | 0.041 | 0.3 |
| mRNA | BRD9876:MK-1775 (4:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.15 | 0.3 |
| mRNA | IC-87114 | CTRPv2 | pan-cancer | AAC | 0.054 | 0.3 |
| mRNA | nintedanib | CTRPv2 | pan-cancer | AAC | 0.046 | 0.3 |
| mRNA | Gemcitabine | gCSI | pan-cancer | AAC | 0.068 | 0.3 |
| mRNA | linifanib | GDSC1000 | pan-cancer | AAC | -0.043 | 0.3 |